Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J.

Nat Struct Biol. 2002 Apr;9(4):268-72.

PMID:
11896401
2.

The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

Regan J, Pargellis CA, Cirillo PF, Gilmore T, Hickey ER, Peet GW, Proto A, Swinamer A, Moss N.

Bioorg Med Chem Lett. 2003 Sep 15;13(18):3101-4.

PMID:
12941343
3.

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

Regan J, Breitfelder S, Cirillo P, Gilmore T, Graham AG, Hickey E, Klaus B, Madwed J, Moriak M, Moss N, Pargellis C, Pav S, Proto A, Swinamer A, Tong L, Torcellini C.

J Med Chem. 2002 Jul 4;45(14):2994-3008.

PMID:
12086485
4.

Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.

Kroe RR, Regan J, Proto A, Peet GW, Roy T, Landro LD, Fuschetto NG, Pargellis CA, Ingraham RH.

J Med Chem. 2003 Oct 23;46(22):4669-75.

PMID:
14561086
5.

The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.

Cirillo PF, Pargellis C, Regan J.

Curr Top Med Chem. 2002 Sep;2(9):1021-35. Review. Erratum in: Curr Top Med Chem. 2002 Dec;2(12):following 1394..

PMID:
12171569
6.

Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.

Simard JR, Getlik M, Grütter C, Pawar V, Wulfert S, Rabiller M, Rauh D.

J Am Chem Soc. 2009 Sep 23;131(37):13286-96. doi: 10.1021/ja902010p.

PMID:
19572644
7.

Discovery and characterization of a substrate selective p38alpha inhibitor.

Davidson W, Frego L, Peet GW, Kroe RR, Labadia ME, Lukas SM, Snow RJ, Jakes S, Grygon CA, Pargellis C, Werneburg BG.

Biochemistry. 2004 Sep 21;43(37):11658-71.

PMID:
15362850
8.

Inhibitor scaffolds as new allele specific kinase substrates.

Kraybill BC, Elkin LL, Blethrow JD, Morgan DO, Shokat KM.

J Am Chem Soc. 2002 Oct 16;124(41):12118-28.

PMID:
12371851
9.

Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.

Trejo A, Arzeno H, Browner M, Chanda S, Cheng S, Comer DD, Dalrymple SA, Dunten P, Lafargue J, Lovejoy B, Freire-Moar J, Lim J, Mcintosh J, Miller J, Papp E, Reuter D, Roberts R, Sanpablo F, Saunders J, Song K, Villasenor A, Warren SD, Welch M, Weller P, Whiteley PE, Zeng L, Goldstein DM.

J Med Chem. 2003 Oct 23;46(22):4702-13.

PMID:
14561090
10.

Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).

Regan J, Capolino A, Cirillo PF, Gilmore T, Graham AG, Hickey E, Kroe RR, Madwed J, Moriak M, Nelson R, Pargellis CA, Swinamer A, Torcellini C, Tsang M, Moss N.

J Med Chem. 2003 Oct 23;46(22):4676-86.

PMID:
14561087
11.

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.

Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM.

J Med Chem. 2003 Sep 11;46(19):3953-6.

PMID:
12954047
12.
13.

The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.

Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst JT, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1772-7. doi: 10.1016/j.bmcl.2008.02.033. Epub 2008 Feb 16.

PMID:
18325768
14.

Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA.

Wang X, Mader MM, Toth JE, Yu X, Jin N, Campbell RM, Smallwood JK, Christe ME, Chatterjee A, Goodson T Jr, Vlahos CJ, Matter WF, Bloem LJ.

J Biol Chem. 2005 May 13;280(19):19298-305. Epub 2005 Feb 28.

15.

The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.

Scapin G, Patel SB, Lisnock J, Becker JW, LoGrasso PV.

Chem Biol. 2003 Aug;10(8):705-12.

16.

Catalysis and function of the p38 alpha.MK2a signaling complex.

Lukas SM, Kroe RR, Wildeson J, Peet GW, Frego L, Davidson W, Ingraham RH, Pargellis CA, Labadia ME, Werneburg BG.

Biochemistry. 2004 Aug 10;43(31):9950-60.

PMID:
15287722
17.

Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong CL, Polmar SH, Olszyna DP, Hack CE, van Deventer SJ, Peppelenbosch MP, van der Poll T.

J Immunol. 2002 Apr 15;168(8):4070-7.

18.

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.

Dumas J, Hatoum-Mokdad H, Sibley R, Riedl B, Scott WJ, Monahan MK, Lowinger TB, Brennan C, Natero R, Turner T, Johnson JS, Schoenleber R, Bhargava A, Wilhelm SM, Housley TJ, Ranges GE, Shrikhande A.

Bioorg Med Chem Lett. 2000 Sep 18;10(18):2051-4.

PMID:
10999468
19.
20.

Signal transduction. MAP kinase signaling specificity.

Weston CR, Lambright DG, Davis RJ.

Science. 2002 Jun 28;296(5577):2345-7. No abstract available.

PMID:
12089430

Supplemental Content

Support Center